Michael L. Moore

1.2k total citations
17 papers, 1.0k citations indexed

About

Michael L. Moore is a scholar working on Infectious Diseases, Virology and Organic Chemistry. According to data from OpenAlex, Michael L. Moore has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Virology and 7 papers in Organic Chemistry. Recurrent topics in Michael L. Moore's work include HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and Neuroendocrine regulation and behavior (3 papers). Michael L. Moore is often cited by papers focused on HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and Neuroendocrine regulation and behavior (3 papers). Michael L. Moore collaborates with scholars based in United States, United Kingdom and Russia. Michael L. Moore's co-authors include Geoffrey B. Dreyer, Brian W. Metcalf, James E. Strickler, Thomas D. Meek, Victoria W. Magaard, Thaddeus A. Tomaszek, Christine Debouck, Thomas J. Carr, Stephen A. Fakhoury and Brian D. Dayton and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Biochemistry.

In The Last Decade

Michael L. Moore

17 papers receiving 989 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael L. Moore United States 13 600 558 419 274 85 17 1.0k
S. Pazhanisamy United States 14 335 0.6× 305 0.5× 477 1.1× 200 0.7× 74 0.9× 23 942
Victoria W. Magaard United States 8 474 0.8× 432 0.8× 337 0.8× 233 0.9× 55 0.6× 8 717
Catherine A. Schaeffer United States 13 475 0.8× 461 0.8× 370 0.9× 123 0.4× 134 1.6× 17 889
Christina Calmels France 21 528 0.9× 521 0.9× 583 1.4× 201 0.7× 142 1.7× 37 1.1k
Sena Garber United States 17 563 0.9× 496 0.9× 340 0.8× 431 1.6× 91 1.1× 23 1.1k
Blanda Stammen United Kingdom 12 505 0.8× 653 1.2× 420 1.0× 273 1.0× 195 2.3× 15 1.4k
Jonathan Chua United States 11 359 0.6× 212 0.4× 489 1.2× 393 1.4× 105 1.2× 17 952
Diane Thibeault Canada 19 794 1.3× 502 0.9× 317 0.8× 145 0.5× 396 4.7× 30 1.4k
François Hamy Switzerland 19 300 0.5× 534 1.0× 1.1k 2.6× 125 0.5× 73 0.9× 34 1.4k
John H. Tatlock United States 9 183 0.3× 137 0.2× 329 0.8× 318 1.2× 34 0.4× 11 737

Countries citing papers authored by Michael L. Moore

Since Specialization
Citations

This map shows the geographic impact of Michael L. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Moore more than expected).

Fields of papers citing papers by Michael L. Moore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Moore. The network helps show where Michael L. Moore may publish in the future.

Co-authorship network of co-authors of Michael L. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Moore. A scholar is included among the top collaborators of Michael L. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Moore. Michael L. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Tian, Xinrong, et al.. (2019). An efficient and practical synthesis of 2,4-substituted pyrido[4,3-d]pyrimidin-5(6H)-ones. Tetrahedron Letters. 60(49). 151312–151312. 2 indexed citations
2.
Hardwicke, Mary Ann, Alan R. Rendina, Shawn P. Williams, et al.. (2014). A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nature Chemical Biology. 10(9). 774–779. 87 indexed citations
3.
Erhard, Karl F., Mary Ann Hardwicke, Hong Lin, et al.. (2012). Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(9). 3198–3202. 42 indexed citations
4.
Jin, Jian, Yonghui Wang, Feng Wang, et al.. (2008). Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureas. Bioorganic & Medicinal Chemistry Letters. 18(20). 5481–5486. 2 indexed citations
5.
Bruch, Richard C., Jiesheng Kang, Michael L. Moore, & Kathryn F. Medler. (1997). Protein kinase C and receptor kinase gene expression in olfactory receptor neurons. Journal of Neurobiology. 33(4). 387–394. 13 indexed citations
6.
Moore, Michael L. & Geoffrey B. Dreyer. (1993). Substrate-based inhibitors of HIV-1 protease. Perspectives in Drug Discovery and Design. 1(1). 85–108. 46 indexed citations
7.
Tomaszek, Thaddeus A., Michael L. Moore, James E. Strickler, et al.. (1992). Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease. Biochemistry. 31(42). 10153–10168. 35 indexed citations
8.
Grant, Stephan K., Michael L. Moore, Stephen A. Fakhoury, Thaddeus A. Tomaszek, & Thomas D. Meek. (1992). Inactivation of HIV-1 protease by a tripeptidyl epoxide. Bioorganic & Medicinal Chemistry Letters. 2(11). 1441–1445. 12 indexed citations
9.
Dayton, Brian D., et al.. (1990). A radiometric assay for HIV-1 protease. Analytical Biochemistry. 188(2). 408–415. 22 indexed citations
10.
Meek, Thomas D., Dennis M. Lambert, Geoffrey B. Dreyer, et al.. (1990). Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature. 343(6253). 90–92. 201 indexed citations
11.
Tomaszek, Thaddeus A., et al.. (1990). Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease. Biochemical and Biophysical Research Communications. 168(1). 274–280. 34 indexed citations
12.
Meek, Thomas D., Brian D. Dayton, Brian W. Metcalf, et al.. (1989). Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease.. Proceedings of the National Academy of Sciences. 86(6). 1841–1845. 155 indexed citations
13.
Moore, Michael L., Stephen A. Fakhoury, Victoria W. Magaard, et al.. (1989). Peptide substrates and inhibitors of the HIV-1 protease. Biochemical and Biophysical Research Communications. 159(2). 420–425. 145 indexed citations
14.
Callahan, James F., et al.. (1989). Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines. Journal of Medicinal Chemistry. 32(2). 391–396. 36 indexed citations
15.
Dreyer, Geoffrey B., Brian W. Metcalf, Thaddeus A. Tomaszek, et al.. (1989). Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.. Proceedings of the National Academy of Sciences. 86(24). 9752–9756. 171 indexed citations
16.
Hempel, Judith C., William F. Huffman, Garland R. Marshall, et al.. (1988). Design, synthesis, and biological activity of a peptide mimic of vasopressin. Journal of Medicinal Chemistry. 31(4). 742–744. 2 indexed citations
17.
Moore, Michael L., et al.. (1984). Synthesis and characterization of iodinated vasopressin antagonists which retain high affinity for the vasopressin receptor. Biochemical and Biophysical Research Communications. 121(3). 878–883. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Pazhanisamy Breakdown of academic impact, for papers by Victoria W. Magaard Breakdown of academic impact, for papers by Catherine A. Schaeffer Breakdown of academic impact, for papers by Christina Calmels Breakdown of academic impact, for papers by Sena Garber Breakdown of academic impact, for papers by Blanda Stammen Breakdown of academic impact, for papers by Jonathan Chua Breakdown of academic impact, for papers by Diane Thibeault Breakdown of academic impact, for papers by François Hamy Breakdown of academic impact, for papers by John H. Tatlock
Rankless by CCL
2026